Intuitive Surgical, Inc.

NasdaqGS:ISRG Stock Report

Market Cap: US$197.2b

Intuitive Surgical Valuation

Is ISRG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ISRG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$247.79
Fair Value
122.9% overvalued intrinsic discount
28
Number of Analysts

Below Fair Value: ISRG ($552.41) is trading above our estimate of fair value ($247.79)

Significantly Below Fair Value: ISRG is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ISRG?

Key metric: As ISRG is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for ISRG. This is calculated by dividing ISRG's market cap by their current earnings.
What is ISRG's PE Ratio?
PE Ratio80x
EarningsUS$2.48b
Market CapUS$197.20b

Price to Earnings Ratio vs Peers

How does ISRG's PE Ratio compare to its peers?

The above table shows the PE ratio for ISRG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average41.6x
BSX Boston Scientific
76.1x17.00%US$157.1b
SYK Stryker
50.8x15.48%US$146.7b
ABT Abbott Laboratories
17.1x-10.10%US$231.3b
MDT Medtronic
22.3x6.78%US$104.1b
ISRG Intuitive Surgical
80x11.98%US$197.2b

Price-To-Earnings vs Peers: ISRG is expensive based on its Price-To-Earnings Ratio (80x) compared to the peer average (41.6x).

Price to Earnings Ratio vs Industry

How does ISRG's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
PAVM PAVmed
0.3x-151.43%US$20.46m
MHUA Meihua International Medical Technologies
1.2xn/aUS$12.98m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
ISRG 80.0xIndustry Avg. 32.1xNo. of Companies9PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: ISRG is expensive based on its Price-To-Earnings Ratio (80x) compared to the US Medical Equipment industry average (32.1x).

Price to Earnings Ratio vs Fair Ratio

What is ISRG's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ISRG PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio80x
Fair PE Ratio39x

Price-To-Earnings vs Fair Ratio: ISRG is expensive based on its Price-To-Earnings Ratio (80x) compared to the estimated Fair Price-To-Earnings Ratio (39x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ISRG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$552.41
US$575.78
+4.23%
11.41%US$675.00US$350.00n/a28
May ’26US$517.18
US$576.03
+11.38%
11.21%US$675.00US$350.00n/a28
Apr ’26US$496.36
US$624.78
+25.87%
11.11%US$711.00US$350.00n/a28
Mar ’26US$573.15
US$632.53
+10.36%
11.16%US$711.00US$350.00n/a28
Feb ’26US$571.88
US$629.37
+10.05%
11.59%US$711.00US$350.00n/a28
Jan ’26US$521.96
US$556.19
+6.56%
14.01%US$650.00US$265.00n/a28
Dec ’25US$542.00
US$536.43
-1.03%
12.81%US$643.00US$265.00n/a26
Nov ’25US$506.34
US$529.70
+4.61%
12.03%US$604.00US$265.00n/a26
Oct ’25US$484.76
US$486.45
+0.35%
12.19%US$586.00US$265.00n/a26
Sep ’25US$492.63
US$482.03
-2.15%
12.39%US$586.00US$265.00n/a26
Aug ’25US$450.94
US$469.35
+4.08%
11.02%US$525.00US$265.00n/a25
Jul ’25US$436.24
US$426.49
-2.24%
11.25%US$500.00US$253.00n/a25
Jun ’25US$402.12
US$423.57
+5.33%
11.01%US$500.00US$253.00n/a25
May ’25US$371.70
US$420.59
+13.15%
10.46%US$475.00US$253.00US$517.1825
Apr ’25US$394.87
US$414.11
+4.87%
10.45%US$475.00US$253.00US$496.3625
Mar ’25US$397.90
US$408.45
+2.65%
12.14%US$475.00US$230.00US$573.1525
Feb ’25US$383.83
US$402.75
+4.93%
13.90%US$475.00US$230.00US$571.8825
Jan ’25US$337.36
US$337.19
-0.051%
13.21%US$400.00US$230.00US$521.9625
Dec ’24US$315.20
US$326.63
+3.63%
12.67%US$400.00US$230.00US$542.0025
Nov ’24US$270.46
US$324.90
+20.13%
12.81%US$400.00US$230.00US$506.3424
Oct ’24US$292.29
US$361.91
+23.82%
10.55%US$400.00US$230.00US$484.7623
Sep ’24US$310.41
US$361.91
+16.59%
10.55%US$400.00US$230.00US$492.6323
Aug ’24US$323.95
US$361.91
+11.72%
10.55%US$400.00US$230.00US$450.9423
Jul ’24US$341.94
US$310.48
-9.20%
10.48%US$365.00US$204.00US$436.2421
Jun ’24US$310.54
US$308.19
-0.76%
10.10%US$365.00US$204.00US$402.1221
May ’24US$303.02
US$305.24
+0.73%
9.59%US$350.00US$204.00US$371.7021
AnalystConsensusTarget
Consensus Narrative from 28 Analysts
US$575.78
Fair Value
4.1% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 16:37
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Intuitive Surgical, Inc. is covered by 61 analysts. 30 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
David ToungArgus Research Company
Richard PurkissAtlantic Equities LLP